Last reviewed · How we verify

GP MDI — Competitive Intelligence Brief

GP MDI (GP MDI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Beta-2 adrenergic receptor and glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GP MDI (GP MDI) — Pearl Therapeutics, Inc.. GP MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GP MDI TARGET GP MDI Pearl Therapeutics, Inc. phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Beta-2 adrenergic receptor and glucocorticoid receptor
Fluticasone Propionate/Salmeterol Combination Product Fluticasone Propionate/Salmeterol Combination Product GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone/Salmeterol Diskus Fluticasone/Salmeterol Diskus Johns Hopkins University marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone/salmeterol in all asthmatics fluticasone/salmeterol in all asthmatics Gelb, Arthur F., M.D. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone propionate/salmeterol combination Fluticasone propionate/salmeterol combination GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone and salmeterol fluticasone and salmeterol University of Chicago marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Fluticasone/Salmeterol HFA Fluticasone/Salmeterol HFA GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP MDI — Competitive Intelligence Brief. https://druglandscape.com/ci/gp-mdi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: